Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen, are driving over 20% growth. The Seagen acquisition is reshaping Pfizer’s growth trajectory, with oncology drug Padcev leading momentum and a strong cost-saving program underway. Despite challenges like patent expirations and debt, Pfizer is expected to see a positive turnaround as cost cuts and new product pillars scale, making it a buy recommendation.
The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to reach $35.10 billion by 2035 with a CAGR of 14.64%. Growth is fueled by advances in gene-silencing RNAi therapies like patisiran and vutrisiran, i...
The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to grow to $35.10 billion by 2035 at a CAGR of 14.64%. Growth is fueled by advances in gene-silencing drugs like patisiran and vutrisiran, improved d...
